Want to see KR:001360 full AI Analyst Report?
Top Page
SAMSUNG PHARMACEUTICAL.CO.,Ltd.
(001360)
Select Model
Select Model
Rating:44Neutral
Price Target:
₩1,216.00
Action:N/A
Date:10/28/26
The score is primarily held down by weak financial performance—large TTM losses and ongoing negative operating/free cash flow—despite a relatively moderate leverage profile. Technicals also contribute negatively as the stock trades below major moving averages with bearish MACD and weak RSI. Valuation provides limited support because the negative P/E reflects unprofitable operations, and no dividend yield data is available.
Positive Factors
Moderate Leverage
Moderate leverage provides a comparatively sound solvency base and limits immediate dependence on debt financing. This gives Samsung Pharmaceutical greater flexibility to manage its operations and pursue improvements while reducing the balance-sheet strain that can accompany heavier borrowing.
Negative Factors
Persistent Cash Burn
Persistent negative operating and free cash flow shows that the core business is not currently funding itself. Continued cash burn can increase reliance on external funding or existing balance-sheet resources, reducing financial flexibility and raising risk if operating losses continue.
Read all positive and negative factors
Positive Factors
Negative Factors
Moderate Leverage
Moderate leverage provides a comparatively sound solvency base and limits immediate dependence on debt financing. This gives Samsung Pharmaceutical greater flexibility to manage its operations and pursue improvements while reducing the balance-sheet strain that can accompany heavier borrowing.
Read all positive factors
SAMSUNG PHARMACEUTICAL.CO.,Ltd. (001360) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩117.74B
Dividend YieldN/A
Average Volume (3M)343.29K
Price to Earnings (P/E)―
Beta (1Y)0.27
Revenue Growth-2.43%
EPS Growth-234.71%
CountryKR
Employees240
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-1451.04
Shares Outstanding94,162,080
10 Day Avg. Volume198,554
30 Day Avg. Volume343,287
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)1.19
Price to Sales (P/S)3.13
P/FCF Ratio-14.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
SAMSUNG PHARMACEUTICAL.CO.,Ltd. Business Overview & Revenue Model
Company Description
SAMSUNG PHARM. Co., LTD. is a South Korean pharmaceutical company engaged in the manufacturing and distribution of a wide array of medical products. Its extensive portfolio includes a variety of prescription medications, encompassing treatments fo...
SAMSUNG PHARMACEUTICAL.CO.,Ltd. Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
58
Neutral
Cash Flow
21
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 42.74B | 46.07B | 44.29B | 51.96B | 51.83B | 54.90B |
| Gross Profit | 16.46B | 14.64B | 19.77B | 22.97B | 24.62B | 9.28B |
| EBITDA | -15.98B | -18.06B | -11.74B | -21.69B | -21.97B | -36.46B |
| Net Income | -137.15B | 11.55B | -14.09B | -24.81B | -25.09B | -40.28B |
Balance Sheet | ||||||
| Total Assets | 121.07B | 167.44B | 128.45B | 93.48B | 117.91B | 145.46B |
| Cash, Cash Equivalents and Short-Term Investments | 9.56B | 16.17B | 10.39B | 4.28B | 55.99B | 64.40B |
| Total Debt | 18.60B | 17.70B | 5.16B | 595.49M | 2.00B | 2.12B |
| Total Liabilities | 48.81B | 46.39B | 22.60B | 15.89B | 15.32B | 18.19B |
| Stockholders Equity | 72.26B | 121.04B | 105.86B | 77.58B | 102.59B | 127.27B |
Cash Flow | ||||||
| Free Cash Flow | -9.75B | -10.10B | -17.68B | -40.44B | -4.95B | -11.23B |
| Operating Cash Flow | -8.80B | -10.05B | -17.30B | -27.66B | -1.91B | -7.16B |
| Investing Cash Flow | -17.81B | -12.19B | -22.34B | -2.64B | 12.82B | 18.99B |
| Financing Cash Flow | 26.08B | 26.02B | 42.72B | -1.42B | -1.00B | -12.21B |
SAMSUNG PHARMACEUTICAL.CO.,Ltd. Technical Analysis
Negative
―
Price Trends
1321.56
Negative
1321.36
Negative
1559.03
Negative
Market Momentum
-22.16
Positive
39.56
Neutral
36.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:001360, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 1323.75, equal to the 50-day MA of 1321.56, and equal to the 200-day MA of 1559.03, indicating a bearish trend. The MACD of -22.16 indicates Positive momentum. The RSI at 39.56 is Neutral, neither overbought nor oversold. The STOCH value of 36.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:001360.
SAMSUNG PHARMACEUTICAL.CO.,Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | ₩141.34B | 8.31 | ― | 3.18% | 7.46% | -14.42% | |
58 Neutral | ₩144.41B | 7.86 | ― | 4.70% | 6.59% | 185.66% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | ₩169.19B | 63.80 | ― | 3.22% | 1.83% | -67.89% | |
49 Neutral | ₩123.84B | 24.66 | ― | 0.97% | 14.83% | 1148.11% | |
47 Neutral | ₩167.66B | -4.41 | ― | 0.96% | -4.54% | -88.02% | |
44 Neutral | ₩117.74B | -0.85 | ― | ― | -2.43% | -234.71% |
* General Sector Average
KR:001360
SAMSUNG PHARMACEUTICAL.CO.,Ltd.
1,251.00
-242.00
-16.21%
KR:000020
Dong Wha Pharm Co., Ltd.
5,210.00
-950.90
-15.43%
KR:000520
Samil Pharmaceutical Co., Ltd.
7,780.00
-1,440.00
-15.62%
KR:003220
Daewon Pharmaceutical Co., Ltd
7,760.00
-5,032.16
-39.34%
KR:214390
Kyongbo Pharmaceutical Co., Ltd.
5,180.00
-579.91
-10.07%
KR:293480
Hana Pharm Co., Ltd.
8,170.00
-3,145.07
-27.80%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.